Oncocyte Corporation (OCX) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

You have joined the meeting as an attendee and will be muted throughout the meeting. Welcome, everyone, and thank you for joining us to discuss Oncocyte's fourth quarter 2024 results. If you have not seen today's shareholder letter, please visit Oncocyte investor relations page at investors.oncocyte.com. Today's prepared remarks build upon the information already shared in this robust letter. Joining us today are OncoSight President and CEO, Josh Riggs, Chief Science Officer, Eki Schutz, and CFO, Andrea James. We also have our analysts with us as panelists. After our prepared remarks, our analysts may ask questions. Attendees may also type questions into the Q&A. Before turning the call over to Josh Riggs, I'd like to go over our safe harbor. The company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts are forward-looking statements. These statements are made pursuant to and within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act of 1995. We encourage you to review the company's SEC filings, including the company's most recent form, 10-K, in subsequent forms 10Q, which identify risks and uncertainties that may cause future actual results or events to differ materially. Please note that the forward-looking statements made during today's call speak only to the date they are made, and Oncocyte undertakes no obligation to update them. And with that, I would like to now turn the call over to Josh Riggs. Thanks, Gabby. Hello, everyone. Thanks for joining. We've gotten a lot done since our update in November. It's great to be closer than ever to having our clinical assay on market. While we detail our 2024 highlights in the shareholder letter, I'll just briefly ...